- cafead Jul 14, 2022 at 07:52: PM
via Summit Therapeutics’ troubled C. difficile medicine may have a path forward after the FDA cleared a section of trail—however, it’s going to be a steep climb.
The California biotech met with the agency last week to discuss lead asset ridinilazole, which failed to outperform the common antibiotic vancomycin in a phase 3 clinical trial at the end of 2021. Summit has been looking for a way to advance the asset anyway, pitching potential partnerships or an acquisition as a way forward in March.
article source
The California biotech met with the agency last week to discuss lead asset ridinilazole, which failed to outperform the common antibiotic vancomycin in a phase 3 clinical trial at the end of 2021. Summit has been looking for a way to advance the asset anyway, pitching potential partnerships or an acquisition as a way forward in March.
article source